Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Inflammatory Bowel Diseases

  Free Subscription


11.02.2019

11 Aliment Pharmacol Ther
1 Am J Gastroenterol
1 BMC Gastroenterol
1 Clin Gastroenterol Hepatol
2 Dig Dis
8 Dig Dis Sci
1 Gut
3 Inflamm Bowel Dis
9 J Crohns Colitis
1 J Gastroenterol
1 Lancet Gastroenterol Hepatol
2 PLoS One
1 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. ADAMS A, Kalla R, Satsangi J
    Editorial: the influence of genetic factors in mediating the effects of tobacco smoke in IBD.
    Aliment Pharmacol Ther. 2018;47:306-307.
    PubMed     Text format    

  2. LANG BM, Beerenwinkel N, Misselwitz B
    Editorial: the influence of genetic factors in mediating the effects of tobacco smoke in IBD-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:307-308.
    PubMed     Text format    

  3. SABINO J, Torres J
    Editorial: the role of colonic inflammation in the progression of liver disease in patients with primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2018;47:439-440.
    PubMed     Text format    

  4. TAO P, Wang SY
    Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated.
    Aliment Pharmacol Ther. 2018;47:443.
    PubMed     Text format    

  5. PRIMAS C, Reinisch S, Novacek G
    Letter: addition of azathioprine to infliximab maintenance therapy in patients with anti-drug antibodies and subclinical inflammation.
    Aliment Pharmacol Ther. 2018;47:544-545.
    PubMed     Text format    

  6. DE SIMONE C
    Letter: what gastroenterologists should know about VSL#3.
    Aliment Pharmacol Ther. 2018;47:698-699.
    PubMed     Text format    

  7. KESHTELI AH, Madsen KL, Mandal R, Boeckxstaens GE, et al
    Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.
    Aliment Pharmacol Ther. 2019 Jan 31. doi: 10.1111/apt.15141.
    PubMed     Text format     Abstract available

  8. CHEN P, Li Y, Li L, Yu Q, et al
    Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 7. doi: 10.1111/apt.15159.
    PubMed     Text format     Abstract available

  9. SHAH A, Morrison M, Burger D, Martin N, et al
    Systematic review and meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 8. doi: 10.1111/apt.15133.
    PubMed     Text format     Abstract available

  10. SHIVAJI UN, Sharratt CL, Thomas T, Smith SCL, et al
    Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 8. doi: 10.1111/apt.15097.
    PubMed     Text format     Abstract available

  11. SAWBRIDGE D, Subramanian S
    Editorial: the IBD-disability index-ready for prime time?
    Aliment Pharmacol Ther. 2018;47:298-299.
    PubMed     Text format    


    Am J Gastroenterol

  12. LUDVIGSSON JF, Mahl M, Sachs MC, Bjork J, et al
    Fracture Risk in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study From 1964 to 2014.
    Am J Gastroenterol. 2019;114:291-304.
    PubMed     Text format     Abstract available


    BMC Gastroenterol

  13. TEW GA, Leighton D, Carpenter R, Anderson S, et al
    High-intensity interval training and moderate-intensity continuous training in adults with Crohn's disease: a pilot randomised controlled trial.
    BMC Gastroenterol. 2019;19:19.
    PubMed     Text format     Abstract available


    Clin Gastroenterol Hepatol

  14. MINER PB JR
    Effect of Treatment on the Risk of Viral Infections in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2019 Feb 1. pii: S1542-3565(19)30137.
    PubMed     Text format    


    Dig Dis

  15. DANESE S, Allez M, van Bodegraven AA, Dotan I, et al
    Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.
    Dig Dis. 2019 Feb 6:1-18. doi: 10.1159/000496739.
    PubMed     Text format     Abstract available

  16. BELTRAN B, Iborra M, Saez-Gonzalez E, Marques-Minana MR, et al
    Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Dig Dis. 2019;37:108-115.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  17. ALTHOFF P, Schmiegel W, Lang G, Nicolas V, et al
    Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn's Disease.
    Dig Dis Sci. 2019;64:204-212.
    PubMed     Text format     Abstract available

  18. PATIL SA, Flasar MH, Lin J, Lingohr-Smith M, et al
    Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.
    Dig Dis Sci. 2019;64:60-67.
    PubMed     Text format     Abstract available

  19. VELAYOS F
    Introduction to the IBD Case Conference Series.
    Dig Dis Sci. 2019;64:50-51.
    PubMed     Text format    

  20. JACOBS JD, Wagner T, Gulotta G, Liao C, et al
    Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease.
    Dig Dis Sci. 2019 Feb 6. pii: 10.1007/s10620-019-5474.
    PubMed     Text format     Abstract available

  21. MOSADEGHI S, Taleban S
    Alternate Settings for Infusions in Inflammatory Bowel Disease Patients: Homing in on Optimal Care.
    Dig Dis Sci. 2019 Feb 6. pii: 10.1007/s10620-019-05480.
    PubMed     Text format    

  22. PERERA LP, Radigan M, Guilday C, Banerjee I, et al
    Presence of Irritable Bowel Syndrome Symptoms in Quiescent Inflammatory Bowel Disease Is Associated with High Rate of Anxiety and Depression.
    Dig Dis Sci. 2019 Feb 6. pii: 10.1007/s10620-019-05488.
    PubMed     Text format     Abstract available

  23. DEVA RAJOO G, Tan L, Lopez A, Lewindon P, et al
    Early Response to Corticosteroid and Baseline C-Reactive Protein Predicts Outcomes in Children with Moderate to Severe Ulcerative Colitis.
    Dig Dis Sci. 2019 Feb 7. pii: 10.1007/s10620-019-05486.
    PubMed     Text format     Abstract available

  24. KIM DW, An JM, Hong SP, Hahm KB, et al
    Predictive Value of Procalcitonin in Acute Severe Ulcerative Colitis: Not Quite PerfeCT?
    Dig Dis Sci. 2019 Feb 7. pii: 10.1007/s10620-019-05481.
    PubMed     Text format    


    Gut

  25. HARPAZ N, Ballentine S, Colombel JF, E Sands B, et al
    Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity.
    Gut. 2019 Feb 5. pii: gutjnl-2018-318137. doi: 10.1136/gutjnl-2018-318137.
    PubMed     Text format    


    Inflamm Bowel Dis

  26. STEINHART AH
    Exit Strategies for Biologic Therapy in IBD: Is It Too Soon to Stop?
    Inflamm Bowel Dis. 2018;24:669-670.
    PubMed     Text format    

  27. BRETON J, Kastl A, Hoffmann N, Rogers R, et al
    Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2019 Feb 4. pii: 5306187. doi: 10.1093.
    PubMed     Text format     Abstract available

  28. SHMIDT E, Suarez-Farinas M, Mallette M, Moniz H, et al
    A Longitudinal Study of Sexual Function in Women With Newly Diagnosed Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2019 Feb 6. pii: 5307860. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Crohns Colitis

  29. LI K, Strauss R, Marano C, Greenbaum LE, et al
    A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials.
    J Crohns Colitis. 2019 Feb 4. pii: 5306493. doi: 10.1093.
    PubMed     Text format     Abstract available

  30. LORES T, Goess C, Mikocka-Walus A, Collins KL, et al
    Integrated psychological care is needed, welcomed and effective in ambulatory Inflammatory Bowel Disease management: Evaluation of a new initiative.
    J Crohns Colitis. 2019 Feb 5. pii: 5307105. doi: 10.1093.
    PubMed     Text format     Abstract available

  31. BROOKS AJ, Norman P, Peach EJ, Ryder AH, et al
    Prospective Study of Psychological Morbidity and Illness Perceptions in Young People with Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Feb 5. pii: 5306964. doi: 10.1093.
    PubMed     Text format     Abstract available

  32. CHEN S, Zuo S, Zhu J, Yue T, et al
    Decreased expression of cystathionine beta-synthase exacerbates intestinal barrier injury in ulcerative colitis.
    J Crohns Colitis. 2019 Feb 5. pii: 5307110. doi: 10.1093.
    PubMed     Text format     Abstract available

  33. HANAUER S, Sandborn WJ, Colombel JF, Vermeire S, et al
    Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in 2 Clinical Trials.
    J Crohns Colitis. 2019 Feb 6. pii: 5308120. doi: 10.1093.
    PubMed     Text format     Abstract available

  34. BRITTO S, Kellermayer R
    Carbohydrate Monotony as Protection and Treatment for Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Jan 30. pii: 5304571. doi: 10.1093.
    PubMed     Text format     Abstract available

  35. CHURCH PC, Ho S, Sharma A, Tomalty D, et al
    Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis.
    J Crohns Colitis. 2019 Jan 23. pii: 5306100. doi: 10.1093.
    PubMed     Text format     Abstract available

  36. DINALLO V, Marafini I, Di Fusco D, Laudisi F, et al
    Neutrophil Extracellular Traps Sustain Inflammatory Signals in Ulcerative Colitis.
    J Crohns Colitis. 2019 Feb 3. pii: 5306154. doi: 10.1093.
    PubMed     Text format     Abstract available

  37. CHAVARRIA C, Casanova MJ, Chaparro M, Barreiro-de Acosta M, et al
    Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicenter Study.
    J Crohns Colitis. 2019 Feb 5. pii: 5306517. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Gastroenterol

  38. NAGANUMA M
    Author's reply: can budesonide form be alterative treatment for ulcerative proctosigmoiditis?
    J Gastroenterol. 2018;53:801-802.
    PubMed     Text format    


    Lancet Gastroenterol Hepatol

  39. DE KOCK I, Delrue L, Hindryckx P
    An optimal METRIC for imaging in small bowel Crohn's disease.
    Lancet Gastroenterol Hepatol. 2018 Jun 15. pii: S2468-1253(18)30197.
    PubMed     Text format    


    PLoS One

  40. CHIBA H, Kakuta Y, Kinouchi Y, Kawai Y, et al
    Correction: Allele-specific DNA methylation of disease susceptibility genes in Japanese patients with inflammatory bowel disease.
    PLoS One. 2019;14:e0212148.
    PubMed     Text format     Abstract available

  41. LANDMAN C, Grill JP, Mallet JM, Marteau P, et al
    Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota.
    PLoS One. 2018;13:e0202587.
    PubMed     Text format     Abstract available


    Scand J Gastroenterol

  42. DIGNASS AU, Siegmund B, Goertz R, Schneidewind G, et al
    Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
    Scand J Gastroenterol. 2019 Feb 8:1-10. doi: 10.1080/00365521.2019.1569124.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: